Sorry try that post again as I didn't mean to have a link in there
Iva the 2nd comment refers to ACL's announcement dated 5th March 2014 ie "Alchemia licences novel FAK Inhibitors from CRT"
Personally I think that's a bit of a leap by BS to say that because of ACL taking on some new compounds that that's a reason that ACL is not confident on the phase 3. Makes sense to keep the pipeline full imo. CEO was also been pretty confident in the presentations either side of that announcement ie the Cowen and Roth conference presentations.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable